Aims: To evaluate the efficacy of GLP-1 receptor agonist daily treatment or GLP-1 receptor weekly treatment in type 2 diabetes.

Methods: A systematic search of MEDLINE, Embase and Cochrane Central Register of Controlled Trials was made from the beginning date to December 2018.

Results: A total of 111 studies were included in the meta-analysis. Compared with placebo, treatment with GLP-1RA daily led to significant decrease in HbA1c from baseline (WMD, -0.78%, P<0.01), significant decrease in weight (WMD, -0.97kg, P<0.01), significant decrease in SBP (WMD, -2.41mmHg, P<0.01). Compared with placebo, treatment with GLP-1RA weekly resulted in significant decrease in HbA1c from baseline (WMD, -1.00%, P<0.01), significant decrease in weight (WMD, -1.33kg, P<0.01), significant decrease in SBP (WMD, -1.41mmHg, P<0.01) (Table 1).

Conclusion: Compared with placebo, in type 2 diabetes patients, treatment with GLP-1 receptor agonist daily and weekly, both resulted in significant decrease in HbA1c, weight and SBP from baseline.

graphic
View largeDownload slide
Disclosure

X. Cai: None. W. Yang: None. S. Zhang: None. L. Ji: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi, Takeda Pharmaceutical Company Limited. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Roche Pharma, Sanofi.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.